TNF and cerebral malaria: Furthermore, some of the hits such as adalimumab, Natalizumab, etanercept, thalidomide, ustekinumab, and canakinumab are anti-TNF monoclonal antibodies and anti-inflammatory agents that could modulate the immune response to severe and cerebral malaria.